Impact of NPM1 mutation levels on EFS in AML
| Interval . | Time, days . | Samples, n . | EFS, P . | RR for 100-fold increase of NPM1 level . | 95% CI . |
|---|---|---|---|---|---|
| First-line | |||||
| 1 | 18-60 | 108 | .014 | 1.07 | 1.013-1.121 |
| 2 | 61-120 | 140 | .001 | 1.08 | 1.032-1.128 |
| 3 | 121-365 | 234 | < .001 | 1.10 | 1.087-1.164 |
| 4 | > 365 | 196 | < .001 | 1.20 | 1.108-1.214 |
| Second-line | |||||
| 1 | 18-60 | 30 | n.s. | ||
| 2 | 61-120 | 36 | n.s. | ||
| 3 | 121-365 | 34 | .006 | 1.307 | 1.090-1.524 |
| 4 | > 361 | 11 | .024 | 1.266 | 1.035-1.498 |
| After alloSCT | |||||
| 1 | Up to 60 | 51 | n.s. | ||
| 2 | 61-120 | 38 | .012 | 1.061 | 1.013-1.108 |
| 3 | 121-365 | 42 | .025 | 1.060 | 1.075-1.113 |
| 4 | > 361 | 7 | n.s. |
| Interval . | Time, days . | Samples, n . | EFS, P . | RR for 100-fold increase of NPM1 level . | 95% CI . |
|---|---|---|---|---|---|
| First-line | |||||
| 1 | 18-60 | 108 | .014 | 1.07 | 1.013-1.121 |
| 2 | 61-120 | 140 | .001 | 1.08 | 1.032-1.128 |
| 3 | 121-365 | 234 | < .001 | 1.10 | 1.087-1.164 |
| 4 | > 365 | 196 | < .001 | 1.20 | 1.108-1.214 |
| Second-line | |||||
| 1 | 18-60 | 30 | n.s. | ||
| 2 | 61-120 | 36 | n.s. | ||
| 3 | 121-365 | 34 | .006 | 1.307 | 1.090-1.524 |
| 4 | > 361 | 11 | .024 | 1.266 | 1.035-1.498 |
| After alloSCT | |||||
| 1 | Up to 60 | 51 | n.s. | ||
| 2 | 61-120 | 38 | .012 | 1.061 | 1.013-1.108 |
| 3 | 121-365 | 42 | .025 | 1.060 | 1.075-1.113 |
| 4 | > 361 | 7 | n.s. |
Impact of NPM1 mutation levels on EFS in AML (Cox regression analysis) during and after first-line therapy (678 samples from 229 patients), after second-line chemotherapy (117 samples from 51 patients), and after alloSCT (154 samples from 53 patients).
alloSCT indicates allogeneic stem cell transplantation; CI, confidence interval; EFS, event-free survival; n.s., not significant; and RR, relative risk.